Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $363,346.99 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Andrew Stewart Plump sold 19,651 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $18.49, for a total transaction of $363,346.99. Following the completion of the sale, the insider owned 261,656 shares of the company’s stock, valued at approximately $4,838,019.44. The trade was a 6.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Andrew Stewart Plump also recently made the following trade(s):

• On Monday, August 10th, Andrew Stewart Plump sold 165,393 shares of Takeda Pharmaceutical stock. The shares were sold at an average price of $17.10, for a total transaction of $2,828,220.30.

Takeda Pharmaceutical Trading Up 0.2%

Shares of TAK stock traded up $0.04 on Friday, hitting $18.17. 1,479,067 shares of the company’s stock traded hands, compared to its average volume of 3,162,046. The stock has a market capitalization of $58.22 billion, a price-to-earnings ratio of 53.44 and a beta of -0.08. The company’s fifty day simple moving average is $16.75 and its 200 day simple moving average is $17.18. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.30. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. Equities analysts forecast that Takeda Pharmaceutical Co. will post 1.54 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TAK. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings downgraded Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently modified their holdings of TAK. Renaissance Technologies LLC lifted its stake in shares of Takeda Pharmaceutical by 14.2% in the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Takeda Pharmaceutical in the fourth quarter worth $998,000. Quantinno Capital Management LP raised its holdings in Takeda Pharmaceutical by 20.6% in the first quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock worth $23,878,000 after purchasing an additional 219,999 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in Takeda Pharmaceutical by 19.0% in the first quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock worth $7,993,000 after purchasing an additional 68,844 shares in the last quarter. Finally, Sivia Capital Partners LLC purchased a new position in Takeda Pharmaceutical during the second quarter valued at $351,000. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.